This discussion examines the key considerations oncologists weigh when choosing between chemotherapy alone or chemotherapy ...
This discussion provides a clear overview of current treatment standards and ongoing challenges in the management of advanced ...
Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored drug conjugate technology for cancer and other diseases, today announced that the first patient has been dosed in its ...
Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...
Longer follow-up in the IMpower010 trial further cemented the value of atezolizumab (Tecentriq) in treating stage II-IIIa non-small cell lung cancer (NSCLC) in patients with tumors expressing PD-L1.
Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. Outcome of chemo-immunotherapy for extensive-stage small-cell lung cancer according ...
Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...
With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback